<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651023</url>
  </required_header>
  <id_info>
    <org_study_id>ShanghaiMHST</org_study_id>
    <nct_id>NCT04651023</nct_id>
  </id_info>
  <brief_title>Shanghai Meiji Health Science and Technology Co., Ltd</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Meiji Health Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Meiji Health Science and Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators performed a randomized double-blind trial to determine the effects of long-term&#xD;
      NnEx ingestion in patients with overweight or obesity. Ninety-five participants (23&lt;BMI&lt;30&#xD;
      kg/m2) were randomly allocated to three groups: a control group, a 1 g/day NnEx group, and a&#xD;
      2 g/day NnEx group. The effects of the consumption of 2 g/day or 1 g/day NnEx for 12 weeks on&#xD;
      indices of adiposity and fasting blood metabolic parameters were compared with those of no&#xD;
      consumption of NnEx.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2009</start_date>
  <completion_date type="Actual">June 20, 2009</completion_date>
  <primary_completion_date type="Actual">May 15, 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in anthropometrix indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>weight in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in anthropometrix indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>height in meters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in anthropometrix indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>body fat in percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in anthropometrix indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>visceral fat in percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in anthropometrix indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>waist in centimeters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in anthropometrix indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>hip in centimeters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>glucose in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>HbA1c in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>TG in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>FFA in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>T-cho in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>HDL-cho in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>LDL-cho in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>ASP in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting biochemical indices during the study</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>BUN in mmol/L</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Over Weight People</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (0g NnEx) per day with or after meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low concentration of NnEx group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (1g NnEx) per day with or after meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high concentration of NnEx group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (2g NnEx) per day with or after meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nelumbo nucifera Leaf Extract</intervention_name>
    <description>Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>high concentration of NnEx group</arm_group_label>
    <arm_group_label>low concentration of NnEx group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a body mass index (BMI) of 23-30 kg/m2&#xD;
&#xD;
          -  Has no history of using any antidiabetic medication&#xD;
&#xD;
          -  Absence of liver, kidney, or heart disease&#xD;
&#xD;
          -  Absence of food allergy and daily tea consumption &lt;2 L&#xD;
&#xD;
          -  Meet all of the above criteria and to follow the instructions given during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Testing delayed for &gt;1 week without justification&#xD;
&#xD;
          -  Difficulty attending the hospital on the required days&#xD;
&#xD;
          -  Lack of data regarding the times of beverage consumption for over 5% of the study&#xD;
&#xD;
          -  Abnormal overeating&#xD;
&#xD;
          -  Test results believed to be unreliable because of the lack of provision of diet and&#xD;
             exercise reports during the fasting period&#xD;
&#xD;
          -  Difficulty drawing blood&#xD;
&#xD;
          -  Poor confidence in the test data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Meiji Health Science and Technology Co., Ltd.</investigator_affiliation>
    <investigator_full_name>Zai-Si Ji, phD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

